# Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma

> **NCT00052624** · PHASE1 · UNKNOWN · sponsor: **Xenova Biomedix**

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **BIOLOGICAL:** transferrin-CRM107

## Key facts

- **NCT ID:** NCT00052624
- **Lead sponsor:** Xenova Biomedix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00052624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00052624, "Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00052624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*